Chiusura precedente | 152,49 |
Aperto | 153,90 |
Denaro | 154,29 x 900 |
Lettera | 154,33 x 800 |
Min-Max giorno | 153,35 - 155,86 |
Intervallo di 52 settimane | 105,56 - 175,91 |
Volume | |
Media Volume | 7.345.593 |
Capitalizzazione | 275,086B |
Beta (5 anni mensile) | 0,81 |
Rapporto PE (ttm) | 22,33 |
EPS (ttm) | 6,97 |
Prossima data utili | 28 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | 5,64 (4,08%) |
Data ex dividendo | 14 apr 2022 |
Stima target 1A | 163,01 |
Licenses Revolutionary Skin Care Compound TFC-1067VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-106
Markets have continued to be volatile for a while as inflation rages. In the past, dividend paying stocks have proven to be good hedges for these kinds of environments.
AbbVie, Inc. (ABBV) stock has jumped in 2021, trailing the market thus far, but still rising decently at +17.1%. And the pharmaceutical giant could rise even more due to strong growth prospects. But another likely reason is Big Money lifting the stock.